Advertisement

Beneficial effects of pravastatincolestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study)

      Abstract

      Secondary prevention of coronary heart disease by antilipidemic therapy beginning at ≥3 months after an acute coronary syndrome is well documented. The impact, however, of immediate initiation of antilipidemic therapy on coronary stenoses and clinical outcome in patients with acute coronary syndrome is unknown. In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of ≤130 mg/dl (group A, n = 70). In controls (group B, n = 56), antilipidemic therapy was determined by family physicians. Quantitative coronary angiography was performed at inclusion, and at 6- and 24-month follow-up. The combined clinical end points were total mortality, cardiovascular death, nonfatal myocardial infarction, need for coronary intervention, stroke, and new onset of peripheral vascular disease. Minimal lumen diameter in group A increased by 0.05 ± 0.20 mm after 6 months and 0.13 ± 0.29 mm after 24 months, whereas it decreased by 0.08 ± 0.20 mm and 0.18 ± 0.27 mm, respectively, in group B (p = 0.004 at 6 months and p <0.001 at 24 months). After 2 years, 29 patients of 56 patients in group B, but only 16 of 70 patients in group A, experienced a clinical end point (p = 0.005; odds ratio 0.28, confidence intervals 0.13 to 0.6). We conclude that pravastatin-based therapy initiated immediately after an acute coronary syndrome is well tolerated and safe, lessens coronary atherosclerosis, and has a pronounced clinical benefit.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
        Lancet. 1994; 344: 1383-1389
        • Sacks F.M
        • Pfeffer M.A
        • Moye L.A
        • Rouleau J.L
        • Rutherford J.D
        • Cole T.G
        • Brown L
        • Warnica J.W
        • Arnold J.M
        • Wun C.C
        • Davis B.R
        • Braunwald E
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • LIPID Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Brown G
        • Albers J.J
        • Fisher L.D
        • Schaefer S.M
        • Lin J.T
        • Kaplan C
        • Zhao X.Q
        • Bisson B.D
        • Fitzpatrick V.F
        • Dodge H.T
        Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
        N Engl J Med. 1990; 323: 1289-1295
        • MAAS Investigators
        Effect of simvastatin on coronary atheroma.
        Lancet. 1994; 344: 633-638
        • Schuler G
        • Hambrecht R
        • Schlierf G
        • Grunze M
        • Methfessel S
        • Hauer K
        • Kubler W
        Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet.
        J Am Coll Cardiol. 1992; 19: 34-42
        • Post Coronary Artery Bypass Graft Trial Investigators
        The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
        N Engl J Med. 1997; 336: 153-163
        • Watts G.F
        • Lewis B
        • Brunt J.N
        • Lewis E.S
        • Coltart D.J
        • Smith L.D
        • Mann J.I
        • Swan A.V
        Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS).
        Lancet. 1992; 339: 563-569
        • Jukema J.W
        • Bruschke A.V
        • van Boven A.J
        • Reiber J.H
        • Bal E.T
        • Zwinderman A.H
        • Jansen H
        • Boerma G.J
        • van Rappard F.M
        • Lie K.I
        Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels.
        Circulation. 1995; 91: 2528-2540
        • Study Group of European Atherosclerosis Society
        Strategies for the prevention of coronary heart disease.
        Eur Heart J. 1987; 8: 77-88
        • Buchi M
        • Hess O.M
        • Kirkeeide R.L
        • Suter T
        • Muser M
        • Osenberg H.P
        • Niederer P
        • Anliker M
        • Gould K.L
        • Krayenbuhl H.P
        Validation of a new automatic system for biplane quantitative coronary arteriography.
        Int J Card Imaging. 1990; 5: 93-103
        • Wunderlich W
        • Fischer F
        • Linderer T
        • Kirkeeide R.L
        Analytic isocenter calibration.
        Angiology. 1995; 46: 577-582
        • Wollschläger H
        • Lee P
        • Zeiher A
        • Solzbach U
        • Bonzel T
        • Just H
        Improvement of quantitative angiography by exact calculation of radiological magnification factors.
        Comp Cardiol. 1985; 12: 359-362
        • Wunderlich W
        • Linderer T
        • Backs B
        • Fischer F
        • Nöhring R
        • Schröder R
        Optimizing edge detection in quantitative coronary arteriography.
        Comp Cardiol. 1993; 20: 583-586
        • Kristiansen G
        • Wunderlich W
        • Fischer F
        • Röhrig B
        • Arntz H.R
        • Horstkotte D
        • Schultheiss H.P
        Accuracy and precision of the analytic calibration method in quantitative coronary arteriography.
        Comput Cardiol. 1996; 23: 553-556
        • Hausleiter J
        • Jost S
        • Nolte C.W
        • Dirschinger J
        • Kastrati A
        • Stiel G.M
        • Wunderlich W
        • Fischer F
        • Linderer T
        • Hausmann D
        • Schomig A
        Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems.
        Coron Artery Dis. 1997; 8: 83-90
        • Wunderlich W
        • Fischer F
        • Morguet A.J
        • Horstkotte D
        • Schultheiss H.P
        Foreshortening display.
        Comp Cardiol. 1998; 25: 437-440
        • Shepherd J
        • Cobbe S.M
        • Ford I
        • Isles C.G
        • Lorimer A.R
        • MacFarlane P.W
        • McKillop J.H
        • Packard C.J
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 33: 1301-1307
        • Salonen R
        • Nyyssonen K
        • Prokkala E
        • Rummukaien J
        • Belder R
        Kuopio Atherosclerosis Prevention Study (KAPS).
        Circulation. 1995; 92: 1758-1764
        • Bertrand M.E
        • McFadden E.P
        • Fruchart J.C
        • Van Belle E
        • Commeau P
        • Grollier G
        • Bassand J.P
        • Machecourt J
        • Cassagnes J
        • Mossard J.M
        • et al.
        Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty.
        J Am Coll Cardiol. 1997; 30: 863-869
        • Weintraub W.S
        • Boccuzzi S.J
        • Klein L
        Lack of effect of lovastatin on restenosis after coronary angioplasty.
        N Engl J Med. 1994; 331: 1331-1337
        • Rosenson R.S
        • Tangney C.C
        Antiatherothrombotic properties of statins.
        JAMA. 1998; 279: 1643-1650
        • Dangas G
        • Badimon J.J
        • Smith D.A
        • Unger A.H
        • Levine D
        • Shao J.H
        • Meraj P
        • Fier C
        • Fallon J.T
        • Ambrose J.A
        Pravastatin therapy in hyperlipidemia.
        J Am Coll Cardiol. 1999; 33: 1294-1304
        • EUROASPIRE Study Group
        A European Society of Cardiology survey of secondary prevention of coronary heart disease.
        Eur Heart J. 1997; 18: 1569-1582
      1. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non–Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578–581.